Related to Strong Phase II NSCLC Trial Data Still Not Translating into Phase III Successes

• BioMimetic Strengthens Arrangement with Novartis for Exclusive Supply of Recombinant Human Platelet-Derived Growth Factor
  
• Novartis Pays Proteus $24M as Part of Sensor-Based Organ-Transplant Product Partnership
  
• Scientists Pinpoint 93-Gene Signature that Predicts Non-Small-Cell Lung Cancer Prognosis
  
• Novartis Gains GenVec’s Preclinical Hearing-Loss and Balance-Disorder Program for $5M
  
• Novartis Nabs Imperial College’s Preclinical Meningitis B Vaccine
  
• Novartis Negotiates Rights to Debiopharm’s Mid-Stage HCV Candidate
  
• Investigators Link Age- and Gender-Specific Gene Profiles in NSCLC to Recurrence-Free Survival
  
• Novartis to Evaluate NasVax Adjuvant Technology
  
• FDA Okays Tarceva as Maintenance Therapy of NSCLC after Chemotherapy
  
• Novartis to Pay $45M Up Front in Cancer Collaboration with Array BioPharma
  
• Tarceva Gains EC Clearance as Maintenance Therapy in NSCLC
  
• Vectura Bags $7.5M as Novartis Starts Phase III Development of COPD Therapy
  
• OSI Accepts Astellas' Increased $4B Cash Takeover Offer
  
• Clovis Signs On to Advance Avila’s Preclinical EGFR Mutant-Selective Inhibitor Program
  
• FDA Partially Lifts Clinical Hold on Merck Serono’s Anticancer Vaccine
  
• Interim Analysis of Novartis’ Osteoarthritis Therapy Suggests Lack of Efficacy Benefit
  
• GenVec and Novartis Cement Hearing Loss Partnership with Manufacturing Deal
  
• Novartis Shells Out $10M for Option to Quark’s Phase II-Stage Synthetic siRNA
  
• Warner Chilcott Acquires Sole U.S. Rights to Novartis’ Marketed Overactive Bladder Drug for $400M
  
• Alnylam to Nix Jobs in the Wake of Novartis Collaboration Ending